2007
DOI: 10.2478/s11687-007-0004-x
|View full text |Cite
|
Sign up to set email alerts
|

Genotoxic effects of albendazole in patients medicated for cystic echinococcosis

Abstract: 57 SummaryCystic echinococcosis (CE) due to Echinococcus granulosus is one of the most important helminthic diseases in Turkey where it constitutes a public health and economic problems. Its mean annual incidence in humans is 4.4/100 000 and the prevalence of the tapeworm agent in domestic animals ranges from 11.2 to 50.7 %. Since 1980s, albendazole has been used for treatment of the disease, and this benzimidazole drug has been considered to be of relatively low toxicity. However, prolonged albendazole therap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2008
2008
2016
2016

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…In the light of studies which refer to adverse effects and high toxicity of anthelmintics to humans (Capleton et al 2006, Nuray et al 2007, Oztas et al 2007, there is a possibility of MRLs and ADIs re-evaluation. Food safety assessments are based on scientific data, which clearly has its limitations (Botsoglou and Fletouris 2000).…”
Section: Discussionmentioning
confidence: 99%
“…In the light of studies which refer to adverse effects and high toxicity of anthelmintics to humans (Capleton et al 2006, Nuray et al 2007, Oztas et al 2007, there is a possibility of MRLs and ADIs re-evaluation. Food safety assessments are based on scientific data, which clearly has its limitations (Botsoglou and Fletouris 2000).…”
Section: Discussionmentioning
confidence: 99%
“…Experiments were carried out on male BALB/c mice (n=165) weighing 20-25 g. Mice were randomly divided into five groups as follows: Group 5 -E. multilocularis infected (as Group 2) and treated with combination of TF and ABZ as above Samples of blood, spleen, and peritoneal macrophages were obtained at the following weeks: 0 (prior infection), 2,4,6,8,10,12,14,18,22, and 26 p.i. from all groups (3 mice per experimental day).…”
Section: Experimental Designmentioning
confidence: 99%
“…The disadvantage of benzimidazoles consists also in irresponsiveness to treatment in some patients and recurrence of the disease after intermission of the therapy [8]. There is still no consensus regarding the effective dosage and duration of treatment [9,10]. Moreover, the immunological status of the host, host susceptibility, and actual stage of infection influence the results of treatment [11].…”
Section: Introductionmentioning
confidence: 99%